Key Highlights

  • The stock rose USD 0.1032, or 15.61%, to USD 0.7642 in regular trading on November 3, 2026.
  • Cash and cash equivalents were USD 5.1 million at June 30, 2026, compared with USD 15.0 million at March 31, 2026.
  • Net loss was USD 8.6 million for the second quarter of 2026 and USD 32.8 million for the first half.
  • The company completed a public offering in August 2026 with about USD 4.8 million in net proceeds.
  • Shareholders approved a Reverse Stock Split range of 1-for-5 to 1-for-12 to support Nasdaq compliance.

What Moved Curis Shares Today (up USD 0.1032, 15.61%)

Curis (NASDAQ:CRIS) rose 15.61% to USD 0.7642 in regular trading on November 3, 2026, a gain of USD 0.1032 from the November 2 close of about USD 0.6610 (calculated). No company press release, regulatory filing or clinical update dated between October 30 and November 3, 2026 was identified as a trigger. The move therefore looks like a bounce in a very low priced biotech stock rather than a response to a disclosed event. At this price the shares are a penny stock, which brings sharp volatility, thin Liquidity and a real risk of further dilution.

What Does the Recent Disclosure Show?

Curis is a clinical-stage biotechnology company whose lead candidate, emavusertib, is an oral inhibitor of IRAK4 and FLT3 being tested in blood cancers. The company reported second quarter 2026 results in mid August 2026, with cash and cash equivalents of USD 5.1 million at June 30, 2026.

That compares with USD 15.0 million at March 31, 2026. Net loss was USD 8.6 million for the quarter and USD 32.8 million for the six months ended June 30, 2026. First half operating expenses fell to USD 21.5 million from USD 23.5 million.

The company sold its Erivedge Royalty stream in the fourth quarter of 2025, so it reported no royalty Revenue in 2026.

What Is Happening With the Emavusertib Programs?

The TakeAim Lymphoma study combines emavusertib with ibrutinib in relapsed or refractory primary central nervous system lymphoma. The company said it is intended to support Accelerated Approval filings, with updated data expected in the first half of 2027.

A second Phase 2 study, TakeAim CLL, pairs emavusertib with zanubrutinib in chronic lymphocytic leukemia. In its first quarter update the company expected data from the first patients in December 2026.

How Strong Is the Balance Sheet?

Funding is the central issue. In January 2026 the company arranged a private Placement of up to USD 80.8 million in gross proceeds, including about USD 20.2 million upfront and three series of warrants exercisable at USD 0.75 per share, each worth up to USD 20.2 million.

In August 2026 it completed a public offering with about USD 4.8 million in net proceeds, within a best-efforts offering of up to USD 13.6 million. Management said cash and offering proceeds should fund operations into the fourth quarter of 2026, and that substantial additional Capital is needed. The company has also flagged Going Concern risk, the need to keep its Nasdaq listing and continued dilution. About 40.0 million shares were outstanding at March 31, 2026, before the later offering.

What Should Readers Watch Next?

The third quarter 2026 Business update is the next scheduled disclosure and should show cash at September 30, 2026 and any runway change. Readers may also watch for the timing of the reverse split, which shareholders have approved but leaves execution to the board, and for Warrant exercises that could raise cash.

Clinical markers include the first TakeAim CLL data and any news on lymphoma enrollment.